Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
2 suscriptores
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Página
1 / 1.539
#1

Threshold Pharmaceuticals, Inc (THLD): Opiniones

Tanto por técnico como por fundamentales.

Muchas gracias a todo el que se anime a contestar.

#2

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Ratios financieros:

Noticias:
18 Nov 2010 08:25am EST

Threshold Pharmaceuticals, Inc. announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. Today's presentation focused on two clinical trials, the 402 trial and the 403 trial. The 402 trial is a Phase 1/2, three arm, multicenter, dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine (Gem) or docetaxel (Doc) or pemetrexed (Pem) in patients with various advanced solid tumors including, but not limited to, advanced or metastatic pancreatic cancer, castrate-resistant prostate cancer (CRPC) and relapsed or refractory non-small cell lung cancer (NSCLC). The 403 trial is investigating TH-302 in combination with doxorubicin (Dox) in patients with advanced soft tissue sarcoma. Additionally, in the gemcitabine treatment arm, median progression free survival (PFS) was 6.4 months (95% CI: 4.7 to 7.7 months). Among the patients with relapsed or refractory NSCLC, median PFS was 4.2 months (95% CI: 2.8 months to not reached). Among the 15 patients with CRPC, 11 (73%) had a PSA decline of at least 50%. Among the patients with soft tissue sarcoma, median PFS was 6.4 months (95% CI: 5.6 to 6.9 months). Overall, hematologic toxicity was acceptable and skin and mucosal toxicities were well managed at current dose levels.

Fuente: Reuters

Consulta los Mejores roboadvisors

#3

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Gracias Enrique por la info facilitada.

#5

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Esta compañía no encajaría con Zeltia?
No sé , la voy a seguir...por si las moscas.

#6

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Si pasa 1.61 fiesta:)

#7

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Volumen bonito,

Figura de vuelta a por los 2$

#8

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Atentos que va fuerte. Esto pinta muy bien

Brokers destacados

Cookies en rankia.com

Utilizamos cookies propias y de terceros con finalidades analíticas y para mostrarte publicidad relacionada con tus preferencias a partir de tus hábitos de navegación y tu perfil. Puedes configurar o rechazar las cookies haciendo click en “Configuración de cookies”. También puedes aceptar todas las cookies pulsando el botón “Aceptar”. Para más información puedes visitar nuestra política de cookies.

Configurar
Rechazar todas
Aceptar